Bioanalytical Testing Services Market

Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2027

Report Code: AST 7644 Jun, 2022, by marketsandmarkets.com

[208 Pages Report] The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period. In 2021, North America accounted for the largest share of the market, followed by Europe. The major factors influencing the growth of the North American market include the well-established pharmaceutical industry, strong presence of major service providers, large number of ongoing clinical trial studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rise in the outsourcing of preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies in the region.

Bioanalytical Testing Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact on the Bioanalytical testing services Market

The COVID-19 pandemic has led to a global healthcare crisis, resulting in widespread economic impact since January 2020. In the optimistic scenario, it could be assumed that the COVID-19 pandemic would create a long-term positive impact on the overall market.

The market was initially negatively impacted by the COVID-19 pandemic. Along with the rest of the world, the pharmaceutical companies shut down their laboratories and industry work was stopped in order to mitigate the pandemic effects. Furthermore, the on-site personnel restrictions had biggest impact on pharmaceutical businesses. Most of the large Pharma companies were completely shut down momentarily. Besides this, the safety restrictions required laboratory areas to implement social distancing, increase disinfecting procedures, require self-monitoring for COVID-19 symptoms and heightened PPE requirements.

Additionally, the clinical sites also experienced reduced enrolment and restricted staff. These challenges combined to reduce anticipated trial sizes and created substantial delays in study timelines. Though, recovery can be seen in most regions, particularly North America and Europe, as services regain normality.

The Asia Pacific market has been sluggish to recover, notably in China and India. In an optimistic scenario, the need for smoother workflows and faster turnaround times could boost the market growth.

Bioanalytical testing services Market Dynamics

DRIVERS: Rising focus on the analytical testing of biologics and biosimilars

Biologics represent one of the most promising new therapeutic areas and are becoming increasingly important in the pharmaceutical market; around 800 products are in the pipeline at present. One of the key reasons for this is the rising prevalence of chronic diseases. However, considering the high cost of biologics and the rising focus of various governments on reducing healthcare costs, the focus on biosimilars has increased in recent years. The impending expiry of the patents and exclusivity periods of biologics have also created opportunities for the development of follow-on biologics or biosimilars. According to GaBi, twelve biologics, with global sales of more than USD 67 billion, are scheduled to go off-patent in major markets by 2020, with more biologics likely to follow.

The expected rise in biosimilar R&D will bring with it a growing demand for the associated bioanalytical testing services—compatibility studies for biosimilars, stability testing, product release testing, and protein analysis of biosimilars—to reduce the risks associated with drug development. Moreover, the introduction of biosimilars and the move toward continuous processing are creating the need for more rapid and sensitive analytical techniques.

Increasing preference for outsourcing analytical testing

Pharmaceutical companies have begun outsourcing several R&D functions that are not core to their internal structure. Companies are trying to be more efficient in the drug development process by focusing on their internal core competencies to bring new products to the market in a more cost-effective manner. Cost reductions, efficiency increases, and optimal staffing are some of the key advantages driving the outsourcing of bioanalytical testing for large companies.

In the pharmaceutical sector, the analytical and testing services were the most-outsourced services, followed by solid-dosage form manufacturing, injectable manufacturing, clinical trials, formulation development, and R&D. This trend is backed by an increase in the numbers, capabilities, and volumes of contract research organization and the liking for specific providers over the long-term as opposed to short-term contracts. In the following years, outsourcing as a strategy is anticipated to gain greater notoriety. When coupled with the growth in biologic and biosimilar R&D, this factor is projected to create a very favorable environment for market development.

The outsourcing of bioanalytical testing services supports pharmaceutical companies lessen risks by avoiding large funds in purchasing analytical equipment and maintaining manpower, particularly when development efforts are in the initial stages. The accessibility of specialized analytical testing service providers with key capabilities to deliver optimal results rapidly has led to growing consideration among pharmaceutical businesses to outsource testing services to third-party service providers.

Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry

Pharmaceutical and biotechnology companies invest heavily in research to come up with breakthrough molecules. The increasing prevalence of infectious and chronic diseases has led to significant investments in the development of new drugs and vaccines among key pharmaceutical companies such as Novartis, Takeda, Sanofi, Eli Lilly, and Pfizer.

Moreover, the outbreak of the COVID-19 pandemic has increased the focus among pharmaceutical and biopharmaceutical companies to develop effective drugs and vaccines against viral infections. In this scenario, establishing effective workflows and processes to reduce the time and costs involved in drug and vaccine development has gained significance. This, in turn, is favoring the outsourcing of bioanalytical testing to specialized service providers.

Rising adoption of the Quality by Design approach

Pharmaceutical companies are progressively adopting the Quality-by-Design (QbD) concept promoted by regulatory agencies such as the EMA and US FDA across the globe to improve the robustness of their manufacturing processes and enhance product quality and manufacturing productivity. The QbD approach in the pharmaceutical industry has evolved over the years with the issuance of ICH Q8 (R2) (Pharmaceutical Development), ICH Q9 (Quality Risk Management), and ICH Q10 (Pharmaceutical Quality System).

QbD ensures product quality and requires process performance characteristics to be scientifically designed to meet specific objectives, not merely empirically derived from the performance of test batches. After recommendations from the FDA in 2013, generic drug manufacturers are also adopting the QbD approach in manufacturing operations.

According to the ICH Q 10 guidelines, analytical methods are a key part of the pharmaceutical quality system. Implementation of analytical QbD (AQbD) in the manufacturing process ensures product quality and performance. There is a huge difference between the traditional and AQbD approaches of analytical method development. The traditional approach does not use statistical calculations and risk assessment, while the AQbD approach utilizes tools such as CQA, ATP, DoE, and risk assessment, which helps to easily identify the risk initially so that quality can be improved.

Furthermore, a rising number of conferences, symposia, workshops, and training courses, especially in emerging countries, have played a crucial role in creating awareness about the benefits of adopting the QbD approach among pharmaceutical and biopharmaceutical manufacturers and research organizations. The increasing acceptance and adoption of the QbD approach among pharmaceutical and biopharmaceutical companies across the globe are expected to play a key role in the growth of the bioanalytical testing services market in the coming years.

RESTRAINTS : Dearth of skilled professionals

The shortage of skilled professionals to handle advanced equipment required for bioanalytical tests is a major factor that is expected to restrain the growth of this market. The US Bureau of Labor Statistics estimated that there would be 18,580 clinical laboratory science (CLS) program vacancies in the country by 2020. However, only 5,000 students graduate from accredited CLS programs each year. This means that educational programs are delivering less than a third of the trained professionals needed. This may hamper the adoption of new technologies and methodologies, thereby limiting the growth of the bioanalytical testing services market in the coming years.

Pricing pressure faced by major players

The bioanalytical testing services market is highly competitive and is expected to grow rapidly in the coming years due to the increasing number of bioanalytical CROs. Additionally, the growing number of contract development and manufacturing organizations (CDMOs) offering bioanalytical services is further expected to intensify the competition in the market. Over the last few years, the number of bioanalytical testing service providers has increased in emerging markets, such as China, India, and Brazil, which is a major challenge for global players. These local or regional analytical testing service providers offer services at lower prices as compared to established bioanalytical testing service providers, thereby increasing the pricing pressure on global players to a certain extent. This is adversely affecting the profit margins of global players, especially in emerging markets. Currently, several global players are focusing on entering into agreements, acquisitions, and collaborations to overcome this challenge, maintain their positions in the global market, and establish a stronghold in local markets characterized by low-priced services. However, the threat of local players will continue to affect the pricing policies of global players in the coming years.

OPPORTUNITIES: Emerging countries in the Asia Pacific region

Emerging markets present significant growth opportunities for providers of healthcare analytical testing services—particularly India and China. Governments in both countries are extensively emphasizing the development of life science infrastructure by undertaking several projects and initiatives to encourage pharmaceutical and biopharmaceutical companies to develop and manufacture drugs for various infectious and chronic diseases.

According to a report from the Indian Pharmaceutical Alliance (IPA), the Indian pharmaceutical industry was growing at a rate of 7–8% and is estimated to register USD 80–90 billion in annual revenue by 2030. Nevertheless, with the support of the government and regulatory bodies, the industry can expand at a pace of 11–12%. The support from government in the form of regulatory assistance and investments is integral step toward the commencement of innovation-led industry growth. Furthermore, the favorable government scenario has helped start-ups by providing them soft loans for pharma industrial R&D projects and a grant-in-aid for clinical trials for creating drugs for neglected diseases.

Besides this, the government is also offering non-fiscal benefits such as backing in research in all systems of medicines, involving setting up facilities and joint research projects for industries and institutions.

Furthermore, in 2020, the Chinese State Drug Administration (SDA) opened up a large market for bioanalytical CROs across the world by allowing Chinese pharmaceutical companies to use clinical trial data from studies conducted outside China for their drug submissions to the SDA. This encouraged global CROs keen to enter the growing Chinese market for pharmaceutical drug testing to expand their Chinese facilities and provide bioanalytical services to pharmaceutical and biotechnology companies.

Rising demand for specialized bioanalytical testing services

Traditionally, pharmaceutical and biopharmaceutical companies outsourced only late-phase drug development and routine processes to analytical testing service providers and conducted the early-phase method development projects and problem-solving activities in-house. However, in recent years, they are increasingly outsourcing testing services much earlier in the product development cycle to focus on their core strengths. Pharmaceutical companies choose to outsource services to CROs mainly to gain access to innovative technologies that accelerate the development of compounds through the product pipeline. For instance, companies such as Pfizer, Merck, and Roche have reduced their in-house testing services to fuel their R&D pipelines to meet the growing demand for new drug molecules for various therapeutic areas.

Currently, many pharmaceutical and biopharmaceutical companies are focusing on building a diverse product portfolio and developing new small and large molecules. Combination products, delivery devices, and reformulated or re-engineered drugs are being developed by companies to cater to the unmet needs in the market.

Pharmaceutical companies are focusing on various specialized testing services such as Liquid Chromatography-Mass Spectrometry (LC/MS), gene expression analysis, wet chemistry analysis of compendia raw materials, and trace metal analysis with Inductively Coupled Mass Spectrometry (ICP-MS). These tests require high-end equipment and skilled professionals. To save equipment and labor costs, pharmaceutical and biopharmaceutical companies prefer to outsource these specialized testing services to CROs.

CHALLENGES: Innovative formulations demanding a unique bioanalytical testing approach

Over the years, competition in the pharmaceutical and biopharmaceutical market to develop cutting-edge therapies and gain the edge of patent exclusivity by quick drug development has increased significantly. In all phases of pharmaceutical and biopharmaceutical development, bioanalytical testing plays a major role and is the most outsourced process among all the chemistry, manufacturing, and control (CMC) activities. CMC data is also pivotal to meet regulatory expectations and acquire Investigational New Drug (IND) approval.

Diversity of CMC requirements for biopharmaceutical IND and the development of novel drug delivery systems pose a variety of challenges and require a myriad of analytical methods for testing new drug molecules. Currently, several service providers are also enhancing their portfolios of service offerings in line with the demand from the pharmaceutical and biopharmaceutical industries. However, they must still keep pace with the current rate of technological changes.

Growing need to improve the sensitivity of bioanalytical methods

One of the prominent challenges in this field is ensuring sufficient sensitivity, speed of analysis, and robustness of methodologies. Changes, fluctuations, and variations in end-user demands and regulatory requirements make it highly difficult for service providers to ensure sufficient testing capabilities; they must constantly look for and implement innovative and new assays. For instance, the evaluation of the placental transfer of certolizumab pegol (CZP) requires highly sensitive and selective bioanalytical assays to measure low CZP concentrations in infant and umbilical cord blood. For this study, the electrochemiluminescence immunoassay was validated for measuring low CZP concentrations in human plasma.

Similarly, there are many challenges faced when optimizing bioassays for biologics that increase timelines and exceed budgets, ending in results that do not satisfy requirements. The reason behind this is early in the process of assay development for biologics, there is limited production experience and incomplete knowledge about assay capabilities. In recent years, innovative assay formats such as reporter gene and second messenger assays have been emerging in drug discovery, and some of these assays have been tried in cell-based assays for drug development as well. However, it is becoming a challenge for service providers, as they have to constantly seek newer sensitive assays to cater to the changing demands of end users.

The cell-based assays accounted for the largest share of the bioanalytical testing services market in 2021

The cell-based assays segment dominated the market in 2021. The increasing prevalence of chronic diseases and the rising number of clinical trials are expected to drive the segment growth.

The Oncology segment dominated this market with the largest share in 2021

The oncology accounted for the largest share of the global bioanalytical testing services market in 2021 and is also expected to grow at the highest CAGR. Surging number of clinical trials conducted for cancer is driving the segment growth.  

The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the bioanalytical testing services market in 2021

The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the global market in 2021. Pharmaceutical and biopharmaceutical companies mainly focus on developing new drugs for the treatment of various diseases. Increased outsourcing of early-phase development, clinical, and laboratory testing services by pharmaceutical companies is expected to drive the segment growth.

Asia Pacific to grow at the fastest CAGR during the forecast period

The APAC market is becoming a key destination for drug development and clinical research. Increase in the number of clinical trial activities in the region is mainly due to reasons such as cost benefits, a large treatment-naοve population, maintenance of participants in clinical trials, and constantly improving regulatory procedures.

Bioanalytical Testing Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Key players in the Bioanalytical testing services market: Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group (UK), Syneos Health (US), ICON (Ireland), Frontage Labs (US), PPD (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs (India), LGS Limited (UK), Sartorius AG (Germany), CD BioSciences (US), Absorption Systems LLC (US), Pace Analytical Services (US), Bioneeds India Private Limited (India) and Vipragen Biosciences (India).

Scope of the bioanalytical testing services market  Report:

Report Metric

Details

Market Size available for years

2020-2027

Base Year Considered

2021

Forecast period

2022-2027

Forecast Unit

Value (USD)

Segments covered

Bioanalytical testing services market :
Type, Application and End User

Geographies covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Companies Covered

Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group (UK), Syneos Health (US), ICON (Ireland), Frontage Labs (US), PPD (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs (India), LGS Limited (UK), Sartorius AG (Germany), CD BioSciences (US), Absorption Systems LLC (US), Pace Analytical Services (US), Bioneeds India Private Limited (India) and Vipragen Biosciences (India).

The research report categorizes the market into the following segments:

Bioanalytical testing services market , By Type

  • Cell-based Assays
  • Bacterial cell-based assays
  • Viral cell-based assays
  • Virology Testing
  • In Vitro Virology Testing
  • In Vivo Virology Testing
  • Species-specific Viral PCR Assays
  • Method Development, Optimization, and Validation
  • Serology, Immunogenicity, and Neutralizing Antibodies
  • Biomarker Testing
  • Pharmacokinetic Testing
  • Other Services

Bioanalytical testing services market , By Application

  • Oncology
  • Neurology
  • Infectious Diseases
  • Gastroenterology
  • Cardiology
  • Other Applications

Bioanalytical testing services market , By End User

Bioanalytical testing services market , by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Recent Developments:

Expansions


Month & Year

Company

Location

Description

February 2022

SGS

Shanghai, China

SGS opened bioanalytical laboratory equipped with leading instrumentation and equipment including a Watson LIMS system and WinNonlin software.

September 2021

SGS

France

SGS opened bioanalytical laboratory to meet the growing demand for bioanalytical testing services to support drug development of small molecules, peptides, biotherapeutics, and cell and gene therapies.

November 2021

LabCorp

Singapore

LabCorp’s announced expansion of its global offerings and its footprint in the Asia-Pacific (APAC) region with the opening of a new, integrated bioanalytical laboratory in Singapore

October 2021

Medpace

North Carolina

Opened new Q² solutions innovation laboratories in North Carolina, creating new jobs and expanded capabilities.

May 2021

PPD

China

PPD opened new multipurpose lab in Suzhou, China, to support Western and China-based pharma and biopharma companies managing China research studies.

February 2020

Frontage Labs

US

Frontage opened a new bioanalytical laboratory in Exton, PA, through its wholly owned subsidiary, Frontage Laboratories, Inc. The new facility includes an additional 10,000 square feet of laboratory space that will enhance its bioanalytical capabilities in biomarkers, biologics, and small-molecule drug development, cell and gene therapy, and high-throughput clinical sample management.

Source: Press Releases

DEALS


MONTH & YEAR

Deal Type

Company 1

Company 2

Description

April 2022

Agreement

WuXi AppTec (China)

A*STAR’s Bioprocessing Technology Institute (Singapore)

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region.

 

 

 

 

 

October 2021

Acquisition

Syneos Health (US)

RxDataScience (US)

This acquisition delivers AI and data engineering expertise, enterprise analytics and technology-enabled solutions to accelerate customer performance

September 2021

Acquisition

Syneos Health (US)

StudyKIK (US)

This acquisition offers sites and sponsors access to technology-enabled, insight-powered solutions, accelerating clinical trial recruitment, retention and diversity 

August 2021

Partnership

Syneos Health (US)

Aetion (US)

This partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies

March 2021

Acquisition

Charles River (US)

Retrogenix (UK)

Charles River Laboratories International, Inc. acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology.

February 2021

Acquisition

ICON plc

PRA Health Sciences Inc. (US)

Services provided by the acquisition will have a broader geographic reach, a deeper understanding of drug therapies and a wider expertise in healthcare technology innovation.

February 2021

Acquisition

Eurofins Scientific

Beacon Discovery (US)

Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development as well as its expertise in GPCR research, complemented by its unique compound library.

November 2020

Collaboration

PAREXEL

Synexa Life Sciences (South Africa)

Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution

January 2020

Partnership

Charles River

Fios Genomics (UK)

This partnership assisted the firm in the sourcing and analysis of high-dimensional, multi-variant datasets associated with drug development.

Source: Press Releases

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 25)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION & SCOPE
           1.2.1 MARKETS COVERED
                    FIGURE 1 BIOANALYTICAL TESTING SERVICES MARKET SEGMENTATION
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH APPROACH
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
          FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET RANKING ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 36)
    FIGURE 7 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 BIOANALYTICAL TESTING SERVICES MARKET: REGIONAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 39)
    4.1 BIOANALYTICAL TESTING SERVICES MARKET OVERVIEW
          FIGURE 11 RISING FOCUS ON ANALYTICAL TESTING OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: MARKET, BY APPLICATION & COUNTRY (2021)
          FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2021
    4.3 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 REGIONAL MIX: MARKET
          FIGURE 14 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 MARKET: DEVELOPING VS. DEVELOPED COUNTRIES
          FIGURE 15 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 43)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 16 BIOANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising focus on the analytical testing of biologics and biosimilars
                                TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
                    5.2.1.2 Increasing preference for outsourcing analytical testing
                    5.2.1.3 Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry
                                FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2017–2024
                    5.2.1.4 Rising adoption of the Quality by Design approach
           5.2.2 RESTRAINTS
                    5.2.2.1 Dearth of skilled professionals
                    5.2.2.2 Pricing pressure faced by major players
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging countries in the Asia Pacific region
                    5.2.3.2 Rising demand for specialized bioanalytical testing services
           5.2.4 CHALLENGES
                    5.2.4.1 Innovative formulations demanding a unique bioanalytical testing approach
                    5.2.4.2 Growing need to improve the sensitivity of bioanalytical methods
    5.3 ASSESSMENT OF COVID-19 IMPACT ON THE ECONOMIC SCENARIO IN THE MARKET

6 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE (Page No. - 50)
    6.1 INTRODUCTION
          TABLE 3 MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 CELL-BASED ASSAYS
          TABLE 4 MARKET FOR CELL-BASED ASSAYS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 5 MARKET FOR CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.1 BACTERIAL CELL-BASED ASSAYS
                    6.2.1.1 Bacterial cell-based assays dominate the market for cell-based assays
                                TABLE 6 MARKET FOR BACTERIAL CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 VIRAL CELL-BASED ASSAYS
                    6.2.2.1 Increasing outbreaks of viral diseases to support the growth of this market segment
                                TABLE 7 BIOANALYTICAL TESTING SERVICES MARKET FOR VIRAL CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 VIROLOGY TESTING
          TABLE 8 MARKET FOR VIROLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 9 MARKET FOR VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 IN VITRO VIROLOGY TESTING
                    6.3.1.1 Higher uptake of in vitro virology assays in the development of anti-viral pharmaceuticals to drive the growth of this market segment
                                TABLE 10 MARKET FOR IN VITRO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 IN VIVO VIROLOGY TESTING
                    6.3.2.1 High utilization of in vivo assays during important production phases to drive their demand
                                TABLE 11 MARKET FOR IN VIVO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.3 SPECIES-SPECIFIC VIRAL PCR ASSAYS
                    6.3.3.1 Wide application of species-specific viral PCR assays in the detection of viral risks to support the growth of this market segment
                                TABLE 12 BIOANALYTICAL TESTING SERVICES MARKET FOR SPECIES-SPECIFIC VIRAL PCR ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION
           6.4.1 MANDATORY REQUIREMENT BY REGULATORY AUTHORITIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 13 MARKET FOR METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES
           6.5.1 INCREASING APPLICATIONS OF SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 14 MARKET FOR SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 BIOMARKER TESTING
           6.6.1 GROWING EMPHASIS ON THE DEVELOPMENT OF PERSONALIZED MEDICINES TO DRIVE THE DEMAND FOR BIOMARKER TESTING SERVICES
                    TABLE 15 MARKET FOR BIOMARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 PHARMACOKINETIC TESTING
           6.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE THE DEMAND FOR PHARMACOKINETIC TESTING SERVICES
                    TABLE 16 MARKET FOR PHARMACOKINETIC TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
    6.8 OTHER SERVICES
          TABLE 17 MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)

7 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION (Page No. - 66)
    7.1 INTRODUCTION
          TABLE 18 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    7.2 ONCOLOGY
           7.2.1 ONCOLOGY IS THE LARGEST APPLICATION SEGMENT IN THE MARKET
                    FIGURE 18 WORLDWIDE CANCER INCIDENCE AND MORTALITY (2018–2040)
                    TABLE 19 BIOANALYTICAL TESTING SERVICES MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 NEUROLOGY
           7.3.1 ROBUST PIPELINE OF DRUGS FOR CNS DISEASES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 20 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
                    TABLE 21 MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 INFECTIOUS DISEASES
           7.4.1 OUTBREAK OF COVID-19 TO BOOST THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 22 MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 GASTROENTEROLOGY
           7.5.1 RISING PREVALENCE OF CHRONIC DIGESTIVE DISORDERS TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 23 MARKET FOR GASTROENTEROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 CARDIOLOGY
           7.6.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 24 BIOANALYTICAL TESTING SERVICES MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 OTHER APPLICATIONS
          TABLE 25 MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

8 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER (Page No. - 76)
    8.1 INTRODUCTION
          TABLE 26 MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
           8.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE THE LARGEST END USERS OF BIOANALYTICAL TESTING SERVICES
                    FIGURE 19 PHARMACEUTICAL R&D SPENDING, 2010–2024
                    TABLE 27 MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
           8.3.1 CDMOS PROVIDE SERVICES SUCH AS ANALYTICAL DEVELOPMENT, FORMULATION SCREENING AND DEVELOPMENT, STABILITY STUDIES, AND PRE-CLINICAL SAFETY ASSESSMENT STUDIES
                    TABLE 28 MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 CONTRACT RESEARCH ORGANIZATIONS
           8.4.1 CONTRACT RESEARCH ORGANIZATIONS ARE INCREASINGLY SUBCONTRACTING THEIR ACTIVITIES TO NICHE LABORATORIES SPECIALIZED IN PROVIDING BIOANALYTICAL TESTING SERVICES
                    TABLE 29 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION (Page No. - 82)
    9.1 INTRODUCTION
          FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
          TABLE 30 MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 21 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT
          TABLE 31 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 32 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 33 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 34 NORTH AMERICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 35 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 36 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US is largest market for bioanalytical testing services in North America
                                TABLE 37 US: KEY INDICATORS
                                TABLE 38 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 39 US: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 40 US: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 41 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 42 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Increasing number of clinical trials in Canada to support market growth
                                TABLE 43 CANADA: KEY INDICATORS:
                                TABLE 44 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 45 CANADA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 46 CANADA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 47 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 48 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE
          TABLE 49 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 50 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 51 EUROPE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 52 EUROPE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 53 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 54 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
                                TABLE 55 GERMANY: KEY INDICATORS
                                TABLE 56 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 57 GERMANY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 58 GERMANY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 59 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 60 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 High number of oncology clinical trials in France to drive market growth
                                TABLE 61 FRANCE: KEY INDICATORS
                                TABLE 62 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 63 FRANCE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 64 FRANCE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 65 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 66 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
                                TABLE 67 UK: KEY INDICATORS
                                TABLE 68 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 69 UK: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 70 UK: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 71 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 72 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Low drug approval time in Italy, along with the growing number of clinical trials, to drive market growth
                                TABLE 73 ITALY: KEY INDICATORS
                                TABLE 74 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 75 ITALY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 76 ITALY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 77 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 78 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising R&D expenditure to boost market growth
                                TABLE 79 SPAIN: KEY INDICATORS
                                TABLE 80 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 81 SPAIN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 82 SPAIN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 83 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 84 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 85 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 86 ROE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 87 ROE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 88 ROE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 89 ROE: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
          FIGURE 22 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT
          TABLE 90 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 91 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 92 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 93 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 94 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 95 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 China is largest market for bioanalytical testing services in Asia Pacific
                                TABLE 96 CHINA: KEY INDICATORS
                                TABLE 97 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 98 CHINA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 99 CHINA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 100 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 101 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Rising geriatric population to drive market growth in Japan
                                TABLE 102 JAPAN: KEY INDICATORS
                                TABLE 103 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 104 JAPAN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 105 JAPAN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 106 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 107 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growing pharmaceutical industry in India to drive market growth
                                TABLE 108 INDIA: KEY INDICATORS
                                TABLE 109 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 110 INDIA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 111 INDIA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 112 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 113 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 114 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 115 ROAPAC: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 116 ROAPAC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 117 ROAPAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 118 ROAPAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA
           9.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
                    TABLE 119 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 120 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 121 LATIN AMERICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 122 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 123 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
                    TABLE 124 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 125 MIDDLE EAST & AFRICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 126 MIDDLE EAST & AFRICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 127 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 128 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 132)
     10.1 INTRODUCTION
             FIGURE 23 KEY DEVELOPMENTS IN BIOANALYTICAL TESTING SERVICES MARKET
     10.2 COMPETITIVE LEADERSHIP MAPPING
             10.2.1 STARS
             10.2.2 EMERGING LEADERS
             10.2.3 PERVASIVE PLAYERS
             10.2.4 PARTICIPANTS
                        FIGURE 24 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
     10.3 MARKET SHARE ANALYSIS
              FIGURE 25 MARKET SHARE ANALYSIS: MARKET (2021)
     10.4 MARKET: GEOGRAPHICAL ASSESSMENT
              FIGURE 26 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN MARKET (2021)
     10.5 COMPETITIVE SITUATIONS & TRENDS
             10.5.1 PRODUCT LAUNCHES (2020–2022)
             10.5.2 EXPANSIONS (2020–2022)
             10.5.3 DEALS (2020–2022)

11 COMPANY PROFILES (Page No. - 139)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     11.1 CHARLES RIVER
              TABLE 129 CHARLES RIVER: BUSINESS OVERVIEW
              FIGURE 27 CHARLES RIVER: COMPANY SNAPSHOT (2021)
     11.2 MEDPACE HOLDINGS
              TABLE 130 MEDPACE HOLDINGS: BUSINESS OVERVIEW
              FIGURE 28 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021)
     11.3 WUXI APPTEC
              TABLE 131 WUXI APPTEC: BUSINESS OVERVIEW
              FIGURE 29 WUXI APPTEC: COMPANY SNAPSHOT (2021)
     11.4 EUROFINS SCIENTIFIC
              TABLE 132 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
              FIGURE 30 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
     11.5 IQVIA INC.
              TABLE 133 IQVIA: BUSINESS OVERVIEW
              FIGURE 31 IQVIA: COMPANY SNAPSHOT (2021)
     11.6 SGS SA
              TABLE 134 SGS SA: BUSINESS OVERVIEW
              FIGURE 32 SGS SA: COMPANY SNAPSHOT (2021)
     11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS
              TABLE 135 LABCORP: BUSINESS OVERVIEW
              FIGURE 33 LABCORP: COMPANY SNAPSHOT (2021)
     11.8 INTERTEK GROUP PLC
              TABLE 136 INTERTEK GROUP PLC: BUSINESS OVERVIEW
              FIGURE 34 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
     11.9 SYNEOS HEALTH
              TABLE 137 SYNEOS HEALTH: BUSINESS OVERVIEW
              FIGURE 35 SYNEOS HEALTH: COMPANY SNAPSHOT (2021)
     11.10 ICON PLC
              TABLE 138 ICON: BUSINESS OVERVIEW
              FIGURE 36 ICON: COMPANY SNAPSHOT (2021)
     11.11 FRONTAGE LABS
              TABLE 139 FRONTAGE LABS: BUSINESS OVERVIEW
              FIGURE 37 FRONTAGE LABS: COMPANY SNAPSHOT (2021)
     11.12 PPD, INC.
              TABLE 140 PPD, INC: BUSINESS OVERVIEW
     11.13 PAREXEL INTERNATIONAL CORPORATION
              TABLE 141 PARAXEL INTERNATIONAL: BUSINESS OVERVIEW
     11.14 ALMAC GROUP
              TABLE 142 ALMAC GROUP: BUSINESS OVERVIEW
     11.15 CELERION
              TABLE 143 CELERION: BUSINESS OVERVIEW
     11.16 ALTASCIENCES
              TABLE 144 ALTASCIENCES: BUSINESS OVERVIEW
     11.17 BIOAGILYTIX LABS
              TABLE 145 BIOAGILYTIX: BUSINESS OVERVIEW
     11.18 LOTUS LABS PVT. LTD.
              TABLE 146 LOTUS LABS: BUSINESS OVERVIEW
     11.19 LGC LIMITED
              TABLE 147 LGC LIMITED: BUSINESS OVERVIEW
     11.20 SARTORIUS AG
              TABLE 148 SARTORIUS AG: BUSINESS OVERVIEW
     11.21 CD BIOSCIENCES INC
              TABLE 149 CD BIOSCIENCES INC: BUSINESS OVERVIEW
     11.22 ABSORPTION SYSTEMS LLC
              TABLE 150 ABSORPTION SYSTEMS LLC: BUSINESS OVERVIEW
     11.23 PACE ANALYTICAL
              TABLE 151 PACE ANALYTICAL: BUSINESS OVERVIEW
     11.24 BIONEEDS INDIA PRIVATE LIMITED
              TABLE 152 BIONEEDS INDIA PRIVATE LIMITED: BUSINESS OVERVIEW
     11.25 VIPRAGEN BIOSCIENCES
              TABLE 153 VIPRAGEN BIOSCIENCES: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 201)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This research study involved the use of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings. Insights from societies and organizations such as the Biotechnology and Biological Sciences Research Council (BBSRC) and the Centers for Disease Control and Prevention (CDC) were also taken into consideration while estimating the market size.

Secondary Research

Secondary research was mainly used to identify and collect information useful for this extensive, technical, market-oriented, and commercial study of the global bioanalytical testing services market. It was also used to obtain key information about the major players and market classification and segmentation according to industry trends. Primary sources mainly included industry experts from core and related industries, preferred service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative insights.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the bioanalytical testing services market. Primary sources from the demand side include experts from pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations, and contract research organizations.

A breakdown of the primary respondents for bioanalytical testing services market  is provided below:

Bioanalytical Testing Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down and bottom-up approaches were used to estimate and validate the size of the global market and various other dependent submarkets. The global bioanalytical testing services market size was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size for market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants.

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.

Objectives of the Study

  • To define, describe, analyze, and forecast the size of the bioanalytical testing services market  on the basis of product, application, end user, and region.
  • To define, describe, and forecast the bioanalytical testing services market by type, application, end user, and region
  • To provide detailed information about the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall bioanalytical testing services market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the bioanalytical testing services market
  • To track and analyze competitive developments such as partnerships, collaborations, agreements, acquisitions, and service launches & expansions in the bioanalytical testing services market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific bioanalytical testing services market  into Australia, New Zealand, and other countries.
Report Code
AST 7644
Published ON
Jun, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Bioanalytical Testing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved